Name: Tesamorelin - Lyophilized Powder
Brand: Aeternum
Price: 111.0 USD
Availability: InStock

GHRH RECEPTOR PHARMACOLOGY¹

How Tesamorelin binds and activates the pituitary GHRH receptor, and how the N-terminal modification influences receptor kinetics relative to native GHRH.

IGF-1AXIS DYNAMICS⁴ ⁷

How endogenous GH released through Tesamorelin engages the IGF-1 axis, including the hepatic conversion of GH to IGF-1.

METABOLIC PATHWAYS⁴

How the GH–IGF-1 axis interacts with substrate metabolism, including pathways studied in hepatic and adipose tissue research.

PULSATILE GH SIGNALING³

How preserving the pulsatile pattern of growth hormone release influences downstream physiology differently than continuous GH elevation.

HYPOTHALAMIC-PITUITARY SIGNALING³

How the broader hypothalamic-pituitary-somatotropic axis responds to receptor-level GHRH stimulation.

LONGEVITY RESEARCH⁵ ⁷

How the GH–IGF-1 axis fits into the broader landscape of ageing biology, where it is one of the most studied signalling systems.

GHRH RECEPTOR PHARMACOLOGY¹

How Tesamorelin binds and activates the pituitary GHRH receptor, and how the N-terminal modification influences receptor kinetics relative to native GHRH.

IGF-1AXIS DYNAMICS⁴ ⁷

How endogenous GH released through Tesamorelin engages the IGF-1 axis, including the hepatic conversion of GH to IGF-1.

METABOLIC PATHWAYS⁴

How the GH–IGF-1 axis interacts with substrate metabolism, including pathways studied in hepatic and adipose tissue research.

PULSATILE GH SIGNALING³

How preserving the pulsatile pattern of growth hormone release influences downstream physiology differently than continuous GH elevation.

HYPOTHALAMIC-PITUITARY SIGNALING³

How the broader hypothalamic-pituitary-somatotropic axis responds to receptor-level GHRH stimulation.

LONGEVITY RESEARCH⁵ ⁷

How the GH–IGF-1 axis fits into the broader landscape of ageing biology, where it is one of the most studied signalling systems.

DISCOVER MORE

Designed in California, Sourced in Great Britain.

A transatlantic standard in peptide research.

Each batch of Tesamorelin is developed across two of the world's most rigorous research environments, combining US scientific design with British precision.

Designed in California
Sourced in Great Britain
Third-Party Purity Verification
Batch-Level Traceability

Format

10mg research peptide

Classification

Complementary peptide blend

Purity

Third-party laboratory tested

Sourcing

Designed in California. Sourced in Great Britain.

Documentation

Certificate of Analysis available upon request

Before You Proceed

Tesamorelin is supplied exclusively as a research compound.

Please review the following carefully:

Not approved for human or veterinary use.

Not for human consumption.

Not intended for diagnosis, treatment or prevention of any condition.

No dosage or administration guidance is provided.

Handle only within appropriate research settings by trained professionals.

Scientific references reflect controlled laboratory research only.

IMPORTANT

Aeternum accepts no responsibility for any use of this compound outside its intended research application.

Tesamorelin in Research

Tesamorelin occupies a distinct position in the peptide research landscape. It is the only synthetic growth hormone-releasing hormone analogue with current FDA approval, first granted in 2010 and re-approved in an updated formulation in 2025. Among peptides studied in modern longevity and metabolic research, very few carry a comparable evidence base. What sustains the research interest is the mechanism itself. Where many growth hormone secretagogues bypass the body's own regulatory system, Tesamorelin works through it binding the same pituitary receptors the body uses to release growth hormone in its natural, pulsatile rhythm. That preservation of physiological signalling is the defining feature of current scientific interest.

What Is Tesamorelin?

Tesamorelin is a synthetic 44-amino-acid peptide analogue of human growth hormone-releasing hormone (GHRH) the naturally occurring hypothalamic peptide that triggers growth hormone release from the pituitary gland. Structurally, Tesamorelin preserves the full 44-amino-acid GHRH sequence with a single chemical modification: an N-terminal trans-3-hexenoic acid group, which increases the molecule's resistance to enzymatic degradation and extends its biological activity compared to native GHRH.
Receptor engagement
Tesamorelin binds the GHRH receptor on pituitary somatotroph cells the same receptor the body uses to initiate growth hormone release. This receptor specificity is what distinguishes GHRH analogues from other classes of growth hormone secretagogues.

Pulsatile release

By acting at the receptor level, Tesamorelin stimulates endogenous growth hormone release in its natural pulsatile pattern, the rhythm in which the pituitary normally secretes growth hormone, rather than producing a flat, sustained elevation.
Downstream signaling
The growth hormone released downstream of Tesamorelin engages the IGF-1 axis, the principal signalling cascade through which growth hormone exerts its effects on tissue.

Curated Bio-Optimization Research

Aeternum curates research compounds for the study of cellular signaling, regenerative pathways, and the molecular systems at the foundation of longevity-led research.

Batch Traceability

Quality Over Scale

Dedicated Research Support

ABOUT US

Bio-Optimization Is the Pursuit

Tesamorelin reflects the research. Aeternum sets the standard.

Frequently Asked Questions

What is Tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH) - the hypothalamic peptide responsible for stimulating growth hormone release from the pituitary. Structurally, it preserves the full GHRH sequence with an N-terminal trans-3-hexenoic acid modification that increases its resistance to enzymatic breakdown.

Is the Tesamorelin supplied by Aeternum FDA-approved?

No. The active molecule has FDA approval as a prescription pharmaceutical for a specific clinical indication, but that approval does not extend to research-grade material supplied for laboratory investigation. Aeternum supplies Tesamorelin strictly for research purposes. Not for human consumption.

Why is Tesamorelin considered distinguished within peptide research?

Tesamorelin is the only synthetic GHRH analogue with current FDA approval. The active molecule was first approved in 2010 and re-approved in an updated formulation in 2025 as a prescription pharmaceutical. This makes it the most extensively characterized molecule in its class with established pharmacokinetics, a documented safety profile, and decades of published clinical literature.

What makes Tesamorelin different from other growth hormone peptides?

Mechanism level. Many growth hormone secretagogues act downstream of the pituitary, bypassing the body's natural regulatory system. Tesamorelin acts at the receptor itself, binding the same pituitary GHRH receptor that responds to endogenous hypothalamic GHRH. This preserves the pulsatile rhythm in which the body naturally releases growth hormone, rather than producing a flat, sustained elevation.

Does Aeternum provide dosage guidance?

No. Tesamorelin supplied by Aeternum is intended strictly for research purposes only. We do not provide dosage recommendations, administration guidance, or medical advice.

What areas of research is Tesamorelin studied in?

Tesamorelin is studied across a broad range of endocrine and metabolic research areas. Active investigation includes GHRH receptor pharmacology, pulsatile growth hormone signalling, the GH–IGF-1 axis, hypothalamic-pituitary regulation, hepatic substrate metabolism, and the role of the GH–IGF-1 system in longevity research.

ASK A QUESTION

References

1

Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291–4304.
View Source
2

FDA Drug Approval Documentation, Egrifta (tesamorelin for injection). U.S. Food and Drug Administration.
View Source
3

Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men. J Clin Endocrinol Metab. 2011;96(1):150–158.
View Source
4

Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389.
View Source
5

Bartke A. Insulin and aging. Cell Cycle. 2008;7(21):3338–3343.
View Source
6

Theratechnologies Inc. Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy. Press release, March 25, 2025
View Source
7

Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22(1):53–74.
View Source

Precision peptides. Elite standards. Designed for a higher standard of living.

Explore

SHOP

Links

STAY INFORMED

Exclusive insights on science, products, and protocols.

Website Developed by demo

Tesamorelin - Lyophilized Powder

Safe & Secure Checkout

A DistinguishedResearch Compound

GHRH RECEPTOR PHARMACOLOGY¹

IGF-1AXIS DYNAMICS⁴ ⁷

METABOLIC PATHWAYS⁴

PULSATILE GH SIGNALING³

HYPOTHALAMIC-PITUITARY SIGNALING³

LONGEVITY RESEARCH⁵ ⁷

GHRH RECEPTOR PHARMACOLOGY¹

IGF-1AXIS DYNAMICS⁴ ⁷

METABOLIC PATHWAYS⁴

PULSATILE GH SIGNALING³

HYPOTHALAMIC-PITUITARY SIGNALING³

LONGEVITY RESEARCH⁵ ⁷

Designed in California, Sourced in Great Britain.

Format

Classification

Purity

Sourcing

Documentation

Before You Proceed

Tesamorelin in Research

What Is Tesamorelin?

Pulsatile release

Curated Bio-Optimization Research

Bio-Optimization Is the Pursuit

Frequently Asked Questions

At the frontier of longevity science

NAD+Lyophilized powder

GHK-CU- Lyophilized powder

BPC-157 / TB-500- Lyophilized powder